PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects is a research paper published in Frontiers in Physiology (2020). On theSindex it has a DataRank of 0.678. It has been cited 91 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.678
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Keywords
Additional file 2 of The LDLR c.501C>A is a disease-causing variant in familial hypercholesterolemia
Additional file 2 of The LDLR c.501C>A is a disease-causing variant in familial hypercholesterolemia
Additional file 1 of Epidemiology of multimorbidity associated with atherosclerotic cardiovascular disease in the United States, 1999–2018
Additional file 1 of Epidemiology of multimorbidity associated with atherosclerotic cardiovascular disease in the United States, 1999–2018
Additional file 1 of Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection
Additional file 1 of Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection
Additional file 1 of The LDLR c.501C>A is a disease-causing variant in familial hypercholesterolemia
Additional file 1 of The LDLR c.501C>A is a disease-causing variant in familial hypercholesterolemia